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AbsTrACT
Wilson disease (WD) is an uncommon recessive 
genetic disorder affecting copper metabolism. Cardiac, 
neurological, hepatic and renal manifestations are well 
defined, nevertheless approximately 30% of patients 
debut with neuropsychiatric symptoms. These psychiatric 
alterations resulting from the accumulation of this heavy 
metal in the basal ganglia are some how less specific. We 
present a short review of psychiatric symptoms of WD and 
describe a case of a 37-year-old woman diagnosed with 
WD who presented neuropsychiatric symptoms and had 
a consequent delay in diagnosis and causal treatment. 
Patients who develop WD starting with a predominance 
of neuropsychiatric symptoms tend to manifest hepatic 
symptoms later, therefore have a longer delay of diagnosis 
and a poorer outcome than patients with hepatic 
symptoms. An early diagnosis of WD can avoid irreversible 
neurological damage.
InTroduCTIon
Wilson disease (WD) is a recessive inherited 
disorder caused by a reduced incorporation 
of copper into ceruloplasmin resulting in the 
accumulation of this metal in different tissues 
especially in the liver, central nervous system, 
heart and kidneys.1
WD was first described by Kinnear Wilson 
as a familial, lethal neurological disease 
accompanied by chronic liver disease leading 
to cirrhosis: it was first called ‘progressive 
lenticular degeneration’.2
Hepatic, neurological, cardiac and renal 
damages occurring in WD have been widely 
studied.3 During the last few years researches 
have focused on establishing the genetic basis 
of this disease, finding the origin of a defect 
at the level of the ATP7B gene which causes 
the mentioned alteration in the metabolism 
of copper.4
Ceruloplasmin level (<20 mg/dL), baseline 
hypercupriuria (>100 µg/24 hours), elevated 
urinary copper excretion after oral admin-
istration of D-penicillamine and mutation 
analysis of the ATP7B gene are helpful for the 
diagnosis of WD.5 6
The psychiatric alterations resulting from 
the accumulation of this heavy metal in the 
basal ganglia are somehow less specific.
revIew of psyChIATrIC feATures of wd
Psychiatric and behavioural alterations in 
WD are very variant in frequency and type 
as they encompass a wide spectrum of symp-
toms. Psychiatric symptoms usually occur in 
2–3 years after the first hepatic and neuro-
logical manifestations and approximately 
in 30% of patients.7 Patients often develop 
behavioural and psychiatric abnormalities 
such as depression, paranoia, delirium, 
hallucinations, irritability, sexual disinhi-
bition, difficulties and worsening results at 
school or work . Changes in personality and 
behaviours such as irritability and aggres-
siveness are the most well-described symp-
toms. Cognitive and behavioural symptoms 
can be reversed after 1–2 years of contin-
uous treatment.8 Psychotic symptoms are 
uncommon in WD. These psychotic symp-
toms normally represent a typical paranoid 
schizophrenia and are associated with very 
severe extrapyramidal signs, but these signs 
are normally interpreted as secondary to 
the use of antipsychotics so it causes a delay 
in diagnosis.9 10 Neuropsychiatric presenta-
tions are more associated with the presence 
of dysarthria and incongruent behaviour 
instead of patients presenting neurological 
symptoms exclusively.11 Some studies had 
reported a higher prevalence of Kayser-
Fleischer ring (copper accumulation in the 
cornea) in individuals with neuropsychiatric 
manifestations.12
In some cases, although it is less frequent, 
the psychiatric symptoms can be the first 
manifestation of the disease.13
The prevalence of psychiatric disorders 
in patients diagnosed with WD has been 
measured in small samples of individuals.
In 1989, Dening and Berrios reported a 
series of 195 cases of WD. Fifty-one per cent 
displayed evidence of any psychopathology 
and twenty percent had a psychiatric inter-
vention before being diagnosed with WD. 
Abnormal behaviours, personality changes, 
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Figure 1 Cranial CT of Wilson disease showed moderate 
subcortical and cortical atrophy, which does not correspond 
to the patient’s age.
the most common psychiatric features. Psychiatric 
symptoms were related to neurological rather than 
hepatic symptoms.11
There is a recent wide review about the psychiatric 
symptoms of WD published in 2014. They conclude that 
psychiatric symptoms can occur before, concurrent with 
or after the diagnosis and treatment of WD. Approxi-
mately 30%–40% of patients display psychiatric manifesta-
tions at the time of diagnosis. When psychiatric symptoms 
preceded neurological or hepatic symptomatology, the 
average time between the occurence of psychiatric symp-
toms and the diagnosis of WD was extremely long(an 
average of 864.3 days). Some gene mutations of ATP7B 
may correlate with specific personality traits changes.14
We found another retrospective natural study with 
a sample of 350 individuals with an average age of 18.8 
years that had psychiatric symptoms. Diagnosis of WD was 
studied in this sample and it turned out that 15 of them 
met the criteria. History of jaundice, family history of 
neuropsychiatric manifestations and sensitivity to neuro-
leptics were the most common findings in those who met 
the criteria.15
In sum, in clinical practice there is a lack in recognition 
of psychiatric symptoms as being due to WD although 
there is a higher prevalence than it has previously been 
thought. It leads to a delay in diagnosis and treatment of 
this disorder and increases the probability of irreversible 
neurological damages.16
CAse reporT
The patient is a 37-year-old gypsy woman with basic 
schooling, possibly with learning difficulties. She has 
no medical or psychiatric background. Family history 
includes a sibling with schizophrenia, another diagnosed 
with acute polymorphic psychotic disorder and alco-
holism, and a sister with intellectual disability.
Disease debases 4 months ago with depressive symp-
toms (apathy, anhedonia) accompanied by social isola-
tion, fatigability, bradypsychia, bradylalia, psychomotor 
slowing and distal tremor. There were no psychotic symp-
toms. Weight loss was up to 6 kg. The patient related that 
the disorder started due to physical mistreatment that she 
received from her current partner.
She was diagnosed with reactive depression and treated 
with selective serotonin reuptake inhibitor (fluoxe-
tine started at 20 mg which increased to 40 mg) for 3 
months. Depressive symptoms did not improve and the 
patient made a suicide attempt by a punctual drug inges-
tion (levomepromazine 300 mg) and was admitted to a 
psychiatric hospital because of persistent suicide ideation. 
During her stance in the emergency room, general evalu-
ation was made with no alterations in haemogram, basic 
biochemistry and coagulation exams. Neuropsychiatric 
exploration revealed sadness, crying, apathy, anhedonia, 
fatigability, bradypsychia, bradylalia, psychomotor slowing 
and distal tremor. All of these symptoms were accompa-
nied with histrionic behaviour.
During the first 3 days, she presented with a sudden 
change in behaviour starting with mutism and very 
striking alterations in gait that were considered as possible 
dissociative symptoms and began treatment with antipsy-
chotics (quetiapine 200 mg/24 hours for a week). This 
temporary diagnosis was based on the recent stressful life 
events that occurred and her personality traits, before an 
extended neurological study was made with more specif-
ical laboratory and image tests. Treatment was not effec-
tive and caused significant extrapyramidal side effects 
such as increased psychomotor slowing, hypertonia and 
tremor.
In later physical and neurological examinations hypo-
mimic face and hyperpigmented complexion (it can be 
explained by her constitutional origin) were the high-
lighted signs as well as other neurological symptoms such 
as cognitive alterations due to motor coordination, ataxic 
march with inability to march in tandem, extrapyramidal 
axial hypertonia, akinesia and tremor.
New behavioural alterations appeared, including poto-
mania, impulsive food intake and mutism accompanied 
by psychotic symptoms such as auditory hallucinations 
‘voices that give orders’.
ComplemenTAry exAms
Cranial CT showed moderate subcortical and cortical 
atrophy, which does not correspond to the patient’s age 
(see figure 1).
MRI skull: density increased in posterior protuberance 
and mesencephalon suggestive of WD (see figure 2).
Blood analysis: ceruloplasmin levels were low in blood, 
copper in urine 70 (normal <70), ceruloplasmin 16.6 
(normal >20).
Ultrasound examination: there was no kidney or 
hepatic damage.
Ophthalmology: no Kaiser-Fleischer ring.
evoluTIon
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Figure 2 MRI showed increased density in posterior 
protuberance and mesencephalon suggestive of Wilson 
disease.
Psychiatric symptoms were first resolved in the first 3 
weeks of treatment with progressive resolution of the 
motor symptoms during the next 12 months (and without 
concomitant antipsychotic drugs) that required antipar-
kinsonian treatment with L-3,4-dihydroxyphenylalanine 
100/carbidopa 25. The patient was discharged after 
2 months of hospitalisation and referred to the neuro-
logical outpatient department. Eighteen months later 
there remained an ataxic march and ceruloplasmin levels 
normalised. No renal or hepatic damage was detected.
Genetic screening for the disease was recommended to 
her relatives with negative results.
dIsCussIon
Literature reviewed according to the present patient 
shows that patients who develop WD starting with a 
predominance of neuropsychiatric symptoms tend to 
manifest symptoms later, and have a longer delay of diag-
nosis and a poorer outcome than patients with hepatic 
symptoms.17
WD is one of the few inherited disorders, which can 
be successfully treated with pharmacological agents (if 
diagnosed early). This is a very important point because 
psychiatric manifestation of WD often leads to diagnosis 
delay, and often to wrong prognosis. Worse prognosis18 as 
well as treatment with D2 antagonist (neuroleptics) often 
leads to irreversible early neurological deterioration19, 
maybe due to decrease of D2 receptors20.
Ethnicity and mistreatment played an important role 
in this patient. Constitutional coloured skin could mask/
overlap possible dermatological changes. Mistreatment 
was explained as the main cause of a reactive depressive 
syndrome joined to a familiar history of mental disease. 
Low neurological signs as bradypsychia, movement retar-
dation and fatigability were considered to be associated 
with the depressive state as well. A diagnosis of WD was 
only considered when important neurological signs 
appeared, such as ataxia, tremor, akinesia and extrapyra-
midal symptoms.
When neuropsychiatric symptoms are detected, brain 
MR or CT may detect structural abnormalities in the 
basal ganglia. Increased density on CT and hyperintensity 
on T2 MRI in the basal ganglia are the most frequently 
found abnormalities as we can also see in our patient’s 
images.21 22
A prospective study of major depression in WD reported 
an incidence of 27%.23 Although it is not clear what mech-
anism is involved in this depression, it is thought that it 
can be a double mechanism: reactive type (by disease) 
and direct type (due to alterations in different brain 
structures). Manic episodes have also been reported.
In terms of treatment, the direct effect of copper 
chelates on depressive symptoms is known. Therefore, a 
combination therapy (copper chelators plus antidepres-
sant) may be a good approach for those patients24 but in 
the present case it is not needed.
In sum, psychiatric manifestations are common in 
WD and can be present at any point in the course of the 
illness. When they occur not associated with hepatic or 
neurological symptoms, there is a high risk of misdiag-
nosis. Diagnosis and appropriate treatment can solve 
psychiatric symptoms in a very short period of time. An 
early diagnosis of WD can avoid irreversible neurological 
damage.16 Sometimes, treatment with copper chelates is 
enough to resolve psychiatric symptoms.
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